609783-06-4

Upstream product

• 609783-03-1 1,1-dimethylethyl {4-bromo-3-[(trifluoromethyl)oxy]phenyl}carbamate 
• 1535-73-5 m-trifluoromethoxyaniline 

Downstream Products

• 609783-12-2 C₁₃H₁₆F₃N₃O₂ 
• 1354948-05-2 4-[5-(chloromethyl)-1H-tetrazol-1-yl]-2-[(trifluoromethyl)oxy]benzonitrile 
• 1354948-04-1 4-[5-(hydroxymethyl)-1H-tetrazol-1-yl]-2-[(trifluoromethyl)oxy]benzonitrile 
• 1354948-03-0 (1-{4-cyano-3-[(trifluoromethyl)oxy]phenyl}-1H-tetrazol-5-yl)methyl acetate 
• 1354948-02-9 2-({4-cyano-3-[(trifluoromethyl)oxy]phenyl}amino)-2-oxoethyl acetate 
• 609783-09-7 4-amino-2-(trifluoromethoxy)benzamide 

Relevant academic research and scientific papers

TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial. Formula (I) wherein A is: (II) or (III)

BENZAMIDE DERIVATIVES

A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.